Roche

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Roche and other ETFs, options, and stocks.

About RHHBY

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. 

CEO
Thomas Schinecker
CEOThomas Schinecker
Employees
103,249
Employees103,249
Headquarters
Basel, Basel-Stadt (Basle Town)
HeadquartersBasel, Basel-Stadt (Basle Town)
Founded
1896
Founded1896
Employees
103,249
Employees103,249

RHHBY Key Statistics

Market cap
291.22B
Market cap291.22B
Price-Earnings ratio
26.51
Price-Earnings ratio26.51
Dividend yield
1.88%
Dividend yield1.88%
Average volume
1.56M
Average volume1.56M
High today
$45.43
High today$45.43
Low today
$44.78
Low today$44.78
Open price
$45.27
Open price$45.27
Volume
321.19K
Volume321.19K
52 Week high
$45.94
52 Week high$45.94
52 Week low
$34.10
52 Week low$34.10

Stock Snapshot

The current Roche(RHHBY) stock price is $45.39, with a market capitalization of 291.22B. The stock trades at a price-to-earnings (P/E) ratio of 26.51 and offers a dividend yield of 1.9%.

As of 2025-11-12, Roche(RHHBY) stock has fluctuated between $44.78 and $45.43. The current price stands at $45.39, placing the stock +1.4% above today's low and -0.1% off the high.

The Roche(RHHBY)'s current trading volume is 321.19K, compared to an average daily volume of 1.56M.

In the last year, Roche(RHHBY) shares hit a 52-week high of $45.94 and a 52-week low of $34.10.

In the last year, Roche(RHHBY) shares hit a 52-week high of $45.94 and a 52-week low of $34.10.

RHHBY News

Nasdaq 3h
RHHBY Reaches Analyst Target Price

In recent trading, shares of RHHBY (Symbol: RHHBY) have crossed above the average analyst 12-month target price of $44.88, changing hands for $45.43/share. When...

RHHBY Reaches Analyst Target Price
TipRanks 1d
Roche upgraded to Hold from Sell at Deutsche Bank

Deutsche Bank analyst Emmanuel Papadakis upgraded Roche (RHHBY) to Hold from Sell with a price target of CHF 265, up from CHF 235. The firm is less cautious on...

Investor's Business Daily 2d
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results

Roche (RHHBY) presented what it called "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics (TGTX)....

TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results

Analyst ratings

48%

of 23 ratings
Buy
47.8%
Hold
30.4%
Sell
21.7%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.